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CHANGES OF THE NITROGEN MONOXIDE
CONCENTRATION IN CHILDREN WITH
PEPTIC ULCER DISEASE
Abstract. The level of nitrogen monoxide is reliable elevated in the blood
and saliva of Helicobacter pylori infected children with ulcer disease, it
decreases by duration of disease more than 3 years, and by severe course
of disease, does not depend on the age of children and localization of
ulcer defect. There was the following distribution of iNOS (G954C)
genotype in patients with UD: homozygotes for G-allele – 47,5%,
heterozygotes – 38,3%, homozygotes for C-allele – 14,2%. The total
prevalence of mutant C-allele of iNOS amounts 52,5%.
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Introduction
In recent years, conceptions of nitrogen monoxide
sources (NO) and its metabolism at the molecular and
cellular levels significantly increased [1]. New infor-
mative methods of determining, experimental models,
new synthesized substances – donors and inhibitors of
NO allows to evaluate the role of NO in many diseases,
including the gastrointestinal tract [3, 5].
We studied correlation between NO secretion of
gastric mucosa and the activity of Helicobacter
pylori (H. pylori) infection. It has been established
that increased production of NO is caused by an
active inflammatory response involved by H. pylori,
which is able to metabolize urea. NO is a stable
compound in acidic conditions and can be used as an
indicator of inflammation [5]. A the positive role of
NO in inhibition of H. pylori infection progression is
known too[7].
We have found that an increased expression of
induced NO-synthase (i-NOS) in gastric mucosa
infected by H. pylori raises the level of NO [4].
Nevertheless, the question of the role of NO in patho-
genesis of ulcer disease (UD) remains unstudied in
pediatric patients, in particular in pediatric gastro-
enterology.
Objective
To increase the effectiveness of prognosis and
treatment of UD in children by optimizing the diag-
nosis and development of complex pathogenetic
therapy of the disease.
Material and methods
We conducted a comprehensive clinical, mole-
cular genetic and laboratory-instrumental exami-
nation of 120 children with UD, aged 7-18 years
(main group) and 100 healthy children of appropriate
age (comparison group), who lived in Chernivtsi and
Chernivtsi region.
The study was conducted using a simple rando-
mization.
The average age of children with UD was 14,8 ±
2,0 years, and healthy children ---– 14,7 ± 2,5 years
(p>0,05). 47,5% of patients of the main group and
52% of patients of comparison group were the
inhabitans of the rural areas. 53,5% of examined
children suffering from UD, were boys. There were
almost equal numbers of children with duration of
UD up to one and over 3 years.
Verification of clinical diagnosis was carried out
in accordance to the treatment of children in
“Children’s Gastroenterology” (Ministry of Health
of Ukraine ¹ 438 of May 26, 2010).
All children were interviewed with studying
anamnestic, genetic, social, environmental, house-
hold and other characteristics.
Clinical studies were performed by the standard
method of patient’s examination. Particular attention
was paid to children’s complaints of pain, its loca-
tion, seasonality, the nature of the factors that
enhanced and relieved the pain.
Paraclinical studies included: complete blood
count, blood chemistries, blood test for glucose,
urinalysis, fecal presence of helminthes eggs, stool
analysis, the study of intestinal microflora.
To verify presence of mucosal ulcers, detection of
refluxes and comorbidity conducted fibroesophago-
gastroduodenoscopy (FEGDS) using fibrogastroduo-
denoscope “Pentax FG-24P” was carried out deter-
mining endoscopic criteria of H. pylori definition and
biopsy of stomach (antrum and body) and duodenal
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mucosa by generally accepted rules of sampling with
the next preparation of smears, staining and bacte-
rioscopy for diagnosis of H. pylori and determination
of the degree of sowing. H. pylori contamination was
confirmed by solid-phase ELISA test by means of
qualitative and quantitative determination of IgG-
antibodies to H. pylori in the serum (UBI MAYIWELL
™, USA). Along with FEGDS was ntragastric pH-
metry using apparatus “IKSH-2” studing of secretory
and alkaline functions of the stomach by the difference
of pH in the body and antrum was carried out.
An ultrasound investigation of the abdominal
cavity organs performed by apparatus “Aloca SSD-
680” according to the conventional method.
Blood for molecular genetic studies and determi-
ning NO concentration was taken from the cubital
vein fasting in the morning.
Collection of 1 ml of saliva was performed fasting
too and after triple rinse of the mouth with distilled
water. The concentration of nitrite in plasma and
saliva was determined using standard. Sodium nitrite
was used as a standard by the method of Golikov P.P.,
et al., 2004.
Amplification of the necessary area of iNOS
promotor was performed by polymerase chain
reaction (PCR) using specific primers (iNOS G954C
direct and iNOS G954C inverse), which were
synthesized by Sigma-Aldrich (Germany). Amount
of DNA for PCR was 50 ng on reaction. DNA
amplification was performed in a medium of the
following composition: 1 × PCR buffer (Hot Start
PCR-buffer, Fermentas, Lithuania), MgCl2 – 3 mM,
a mixture of dNTP – 0,4 mM of each, primers – 1
mM of each, DNA polymerase (Maxima Hot Start
Taq DNA Polymerase, Fermentas) – 3 units of
activity in the sample. The total volume of the
reaction mixture was 50 mkl. PCR was performed
using Thermocyclers PTC-100 (MJ Research Inc,
USA). Analysis of PCR was carried out by
electrophoresis in 2% agarose gel using trysborat
buffer. To visualize DNA fragments, gel stained with
ethidium bromide and photographed under
ultraviolet light on the installation GelDoc 2000
(BioRad, USA). To determine the length of the
obtained fragments, their electrophoretic mobility
compared with mobility of the DNA-marker Gene
Ruler DNA Lader Mix (Fermentas).
For genotyping iNOS, in terms of single
nucleotide substitution G954C, obtained PCR
products were treated with restriction Eco31 I (Bsa
I). Processing of PCR-product restriction was
performed according to the enzyme manufacturer’s
recommendations (Fermentas). These restricted
fragments were analyzed by electrophoresis in 2%
agarose gel.
The results of investigation were evaluated using
descriptive, correlative methods and analysis of
variance. We used statistical modules “Fundamentals
of Statistics” and  “Correlation analysis”, methods of
biostatistics and clinical epidemiology (computing of
the associative links between etiological factors and
UD using non-parametric test of Pearson (÷2), odds
ratio (OR) with 95% confidence interval (CI).
Results and discussion
The level of NO in plasma of children with UD
was (11,62 ± 0,9) mmol/l wich is in 1,36 times lower
than in the comparison group of children (15,84 ±
0,8) mmol/l, p<0,05. The level of NO in saliva in
children of the main group was (41,06 ± 1,9) mmol/
l and it’s in 1,37 times lower than in comparison
group of patients (56,08 ± 1,8) mmol/l, p<0,05. The
rate of NO reduction in plasma and saliva did not
differ significantly, which may indicate a direct
equivalent of the NO content in plasma and saliva.
Probable difference between the NO indices
according to age and gender in intra analysis in both
groups of children was not found (p>0,05). This fact
allows to use present index regardless of age and
gender. Probable strong direct correlation between
the NO level in plasma and saliva was found in
children of main group aged 7-12 years and 13-18
years (r = 0,82 and r = 0,84 respectively, p<0,05),
which indicates the possibility of using of NO levels
in saliva as a marker of NO concentration in the
blood. It has been established that the NO level is
independent of ulcer location.
In cases of H. pylori-negative ulcer the NO level
in biological fluids was significantly higher (16,89 ±
0,8 mmol/l in plasma and 50,66 ± 1,6 mmol/l  in
saliva) as compared with group of H. pylori-positive
patients (11,27 ± 0,7 mmol/l in plasma and 38,15 ±
1,4 mmol/l in saliva, p<0,05). Probable strong direct
correlation between the NO level in plasma and
saliva was established in both variants of disease
(r=0,86 and r=0,88 respectively, p <0,05).
The NO concentration in biological fluids was
significantly higher in children who suffered from
UD less than 1 year (11,63 ± 0,4 mmol/l in plasma
and 41,23 ± 1,2 mmol/l in saliva) and 1-3 years
(11,74 ± 0,3 mmol/l in plasma and 41,67 ± 1,1 mmol/
l in saliva) as compared with patients whose disease
duration was more than 3 years (9,42 ± 0,6 mmol/l in
plasma and 35,40 ± 1,1 mmol/l in saliva); in the acute
stage (11,13 ± 0,6 mmol/l in plasma and 42,47 ± 1,0
mmol/l in saliva) compared with remission (9,47 ±
0,5 mmol/l in plasma and 38,04 ± 1,1 mmol/l in
saliva); with light and medium courses of disease
(12,21 ± 0,4 mmol/l in plasma and 44,58 ± 1,0 mmol/
l in saliva and 11,75 ± 0,3 mmol/l in plasma and
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40,17 ± 1,1 mmol/l in saliva, respectively) in compa-
rison with the severe course (9,03 ± 0,5 mmol/l in
plasma and 33,46 ± 1,2 mmol/l in saliva); with sizes
of ulcer 1-2 mm (12,61 ± 0,31 mmol/l in plasma and
45,37 ± 1,1 mmol/l in saliva) and 3-5 mm (11,19 ±
0,2 mmol/l and 38,90 ± 1,0 mmol/l in saliva) as
compared with the NO level by ulcer size > 6 mm
(10,13 ± 0,6 mmol/l in plasma and 36,21 ± 0,9 mmol/
l in saliva), p <0,05.
Significantly higher concentration of NO in
plasma (12,16 ± 0,3 mmol/l) and saliva (43,35 ± 1,1
mmol/l) was observed in the presence of duodeno-
gastral reflux in comparison with patients with
gastroesophageal reflux (10,03 ± 0,2 mmol/l in
plasma and 38,21 ± 1,0 mmol/l in saliva), p<0,05.
Significantly higher NO level in plasma (13,95 ± 0,9
mmol/l) was in patients with increased acid
productive function of the stomach as compared with
patients with normal stomach acid production (10,25
± 0,7 mmol/l) with a similar trend in saliva, p <0,05.
Molecular genetic studies of children with UD
(identification of G954S polymorphism of iNOS
gene promotor in terms of single nucleotide sub-
stitutions)  was conducted  considering the impor-
tance and relevance of the NO value in the pathology
of gastrointestinal tract (tab.,  fig.) [4, 7].
“Wild” G allele and GG genotype met with
almost equal frequency in children of both groups
(p>0,05). This indexes of UD were less than one,
indicating a possible protective effect of this allele
and genotype.
There was the following distribution of  iNOS
(G954C) genotype in patients with UD: homozygotes
for G-allele – 47,5%, heterozygotes – 38,3%, homo-
zygotes for C-allele – 14,2%. The total prevalence of
mutant C-allele of iNOS amounts 52,5%. Analysis of
epidemiological indicator of UD showed that risk of
the disease development increases in 1,3 times by the
presence of GC genotype and  in 3,9 times by the
presence of genotype CC. It should be noted, that CC
genotype was diagnosed in children with complicated
course of UD.
The frequency distribution of genotypes accor-
ding to gender, in general, was almost the same both
for children of the main group and children of the
group of comparison.
Probable higher level of NO in biological fluids
was observed in patients of main group and
homozygotes for G-allele of comparison group, and
probably lower – in homozygotes for C-allele
(p<0,05). In heterozygotes NO concentration was
significantly lower, and in children with CC genotype
was higher than in patients with GG genotype
(p<0,05). We found a strong direct correlation
between the NO level in children with UD and the
presence of GG genotype in this category of children
(r=0,97, p<0,05) and a strong probable inverse
correlation with CC genotype (r=-0,96, p <0,05).
The presence of abnormal C allele worsens the
course of disease and contributes to larger size of ulcer
defect. In homozygotes with GG genotype size of ulcer
defect was significantly lower as to heterozygotes and
homozygotus persons by C allele (p<0,05) in the
tendency to its increase in patients with CC genotype as
compared with heterozygotes (p<0,05).
Conclusions
1. Equivalent correspondence of the nitrogen
monoxide content in saliva (41,06 ± 1,9) mmol/l and
plasma (11,62 ± 0,9) mmol/l of children with peptic
ulcer disease, and probably its lower its rates in
children of comparison group (in saliva (56,08 ± 1,8)
mmol/l and plasma (15,84 ± 0,8) mmol/l) has been
established. NO level in the blood is significantly
lower in H. pylori-associated ulcer disease, duration
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of disease more than 3 years, remission, severe clini-
cal course, ulcers sizes more than 6 mm (p<0,05),
significantly higher – by increased of acid productive
function of the stomach, presence of duodenolgastric
reflux (p<0,05) and is independent upon age, sex,
and localization of ulcer defects.
2. In patients with peptic ulcer disease distri-
bution of iNOS genotype (G954C) was the next:
homozygotes for G-allele – 47,5%, heterozygotes –
38,3%, homozygotes for C-allele – 14,2%. The total
prevalence of mutant C-allele iNOS was 52,5%. CC
genotype of iNOS gene (G954C) increases the risk of
ulcer disease in 3,9 times (CI [0,21-73,83], x2 =9,6,
p=0,0007).
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Í²ÒÐÎÃÅÍÓ Â Ä²ÒÅÉ, ÕÂÎÐÈÕ ÍÀ ÂÈÐÀÇÊÎÂÓ
ÕÂÎÐÎÁÓ
Ò. Â. Ñîðîêìàí, Ä. Ð. Àíäð³é÷óê, Ñ. Â. Ñîêîëüíèê,
². Ä. Øêðîáàíåöü, Ë. Þ. Õëóíîâñüêà
Ðåçþìå. Ó ä³òåé, õâîðèõ íà âèðàçêîâó õâîðîáó, ð³âåíü
ìîíîîêñèäó í³òðîãåíó äîñòîâ³ðíî ï³äâèùåíèé â êðîâ³ òà
ñëèí³ ïðè ãåë³êîáàêòåðí³é ³íôåêö³¿, çíèæóºòüñÿ ïðè òðèâà-
ëîñò³ çàõâîðþâàííÿ á³ëüøå òðüîõ ðîê³â, òà ïðè òÿæêîìó ïå-
ðåá³ãó õâîðîáè, íå çàëåæèòü â³ä â³êó äèòèíè, ëîêàë³çàö³¿ âè-
ðàçêîâîãî äåôåêòó. Ó õâîðèõ íà âèðàçêîâó õâîðîáó ðîçïîä³ë
ãåíîòèïó iNOS (G954C) áóâ íàñòóïíèì: ãîìîçèãîòí³ îñîáè
ïî G-àëåëþ – 47,5 %, ãåòåðîçèãîòí³ îñîáè – 38,3 %, ãîìîçè-
ãîòí³ îñîáè ïî C-àëåëþ – 14,2 %. Çàãàëüíà ïîøèðåí³ñòü
ìóòàíòíîãî C-àëåëÿ iNOS ñòàíîâèòü 52,5 %.
Êëþ÷îâ³ ñëîâà: âèðàçêîâà õâîðîáà, ìîíîîêñèä í³òðîãå-
íó, ä³òè, ³íäóêîâàíà ñèíòàçà ìîíîîêñèäó í³òðîãåíó.
Áóêîâèíñüêèé äåðæàâíèé ìåäè÷íèé óí³âåðñèòåò,
ì. ×åðí³âö³
ÈÇÌÅÍÅÍÈß ÊÎÍÖÅÍÒÐÀÖÈÈ ÌÎÍÎÎÊÑÈÄÀ
ÀÇÎÒÀ Ó ÄÅÒÅÉ, ÁÎËÜÍÛÕ  ßÇÂÅÍÍÎÉ
ÁÎËÅÇÍÜÞ
Ò. Â. Ñîðîêìàí, Ä. Ð. Àíäðåé÷óê, Ñ. Â. Ñîêîëüíèê,
È. Ä. Øêðîáàíåö, Ë. Þ. Õëóíîâñêàÿ
Ðåçþìå. Ó äåòåé ñ ÿçâåííîé áîëåçíüþ óðîâåíü ìîíî-
îêñèäà àçîòà äîñòîâåðíî ïîâûøåí â êðîâè è ñëþíå ïðè
õåëèêîáàêòåðíîé ÿçâåííîé áîëåçíè, ñíèæàåòñÿ ïðè äëè-
òåëüíîñòè çàáîëåâàíèÿ áîëåå òðåõ ëåò è ïðè òÿæåëîì
òå÷åíèè áîëåçíè, íå çàâèñèò îò âîçðàñòà ðåáåíêà, ëîêàëè-
çàöèè ÿçâåííîãî äåôåêòà. Ó áîëüíûõ ÿçâåííîé áîëåçíüþ
ðàñïðåäåëåíèå ãåíîòèïà iNOS (G954C) áûëî ñëåäóþùèì:
ãîìîçèãîòíûå îñîáè ïî G-àëåëè – 47,5 %, ãåòåðîçèãîòíûå
îñîáè – 38,3 %, ãîìîçèãîòíûå îñîáè ïî C-àëåëè – 14,2 %.
Îáùàÿ ðàñïðîñòðàíåííîñòü ìóòàíòíîé C-àëåëè iNOS
ñîñòàâëÿåò 52,5 %.
Êëþ÷åâûå ñëîâà: ÿçâåííàÿ áîëåçíü, ìîíîîêñèä àçîòà,
äåòè, èíäóöèðîâàííàÿ  ñèíòàçà ìîíîîêèäà àçîòà.
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